Jul 9, 2014, 7:28 PM
News Code: 2720812
0 Persons
Anti-clot drug mass production possible

Tehran, July 9, IRNA -- Recombinant proteins, particularly tissue plasminogen activator (tPA), were produced by the Agriculture Faculty of Tehran's Tarbiat Modarres University.

As an enzyme, tPA is a protein involved in the breakdown of blood clots. It catalyzes the conversion of plasminogen to plasmin, a major enzyme responsible for clot breakdown.

According to the team manager, Dr. Babak Latif, the imported clot-busting drug tPA costs a patient $2,900 per use.

Dr. Latif added that the indigenization of drug production technology by gene transfer to chloroplast provides a promising prospect for its mass production at a much lower cost.

The most common use of the drug is for ischemic stroke. In an ischemic stroke, blood supply to part of the brain is decreased, leading to dysfunction of the brain tissue in that area.